Shanthi Mogali, MD

Profile Headshot

Overview

Shanthi Mogali, MD is an Assistant Professor of Clinical Psychiatry in the Department of Psychiatry at the College of Physicians and Surgeons of Columbia University and is also a Research Psychiatrist at the New York State Psychiatric Institute. She is a board-certified psychiatrist in General and Addiction psychiatry. She obtained her medical degree from Meharry Medical College (2002) and completed residency training at Emory University School of Medicine (2009). Following residency, she completed a clinical research fellowship in Addiction Psychiatry at Columbia University (2011).

Academic Appointments

  • Assistant Professor of Clinical Psychiatry

Gender

  • Female

Credentials & Experience

Education & Training

  • MD, 2005 Meharry Medical College School of Medicine, Nashville, TN
  • Residency: 2009 Emory University School of Medicine
  • Fellowship: 2011 Columbia College of Physicians and Surgeons

Honors & Awards

1998-2001, Howard Hughes Research Scholar for Undergraduate Microbiology, Fisk University
2002-2005, Merit Based General Endowed Scholarship
2008, Indo-American Psychiatric Association Outstanding Resident Award Nominee
2011, Columbia University, Substance Abuse Division Pilot Study Grant: Funding Recipient
2011, NIDA Director’s Travel Award, College on Problems of Drug Dependence

Research

As a fellow, Dr. Mogali received pilot funding for her study examining microglial inhibitors in opioid abusers (manuscript in preparation for publication) and completed a secondary analysis of data collected to determine demographic factors of patients that may predict completion of a rapid naltrexone detoxification. As an Instructor, Dr. Mogali co-authored a chapter on Treatment of Pain and Opioid Use in the textbook, "Research and Development of Opioid-Related Ligands" and co-authored a review article on combination drug use of opioids, benzodiazepine and alcohol. She received mentorship in opioid research in the human laboratory setting under Dr. Sandra Comer, Ph.D. Dr. Mogali currently serves as the research psychiatrist for the opioid laboratory. Her research interests include medication development and opioid self-administration studies that may influence treatment of opioid use disorders.

Selected Publications

Mogali S, Askalsky P, Madera G, Jones JD, Comer SD. Minocycline attenuates 
oxycodone-induced positive subjective responses in non-dependent, recreational
opioid users. Pharmacol Biochem Behav. 2021 Oct;209:173241. doi:
10.1016/j.pbb.2021.173241. Epub 2021 Jul 21. PMID: 34298029; PMCID: PMC8429209.

Brandt L, Jones JD, Martinez S, Manubay JM, Mogali S, Ramey T, Levin FR,
Comer SD. Effects of lorcaserin on oxycodone self-administration and subjective
responses in participants with opioid use disorder. Drug Alcohol Depend. 2020
Mar 1;208:107859. doi: 10.1016/j.drugalcdep.2020.107859. Epub 2020 Jan 17. PMID:
31980285; PMCID: PMC7063580.

Jones JD, Mumtaz M, Manubay JM, Mogali S, Sherwin E, Martinez S, Comer SD.
Assessing the contribution of opioid- and dopamine-related genetic polymorphisms
to the abuse liability of oxycodone. Pharmacol Biochem Behav. 2019
Nov;186:172778. doi: 10.1016/j.pbb.2019.172778. Epub 2019 Sep 4. PMID: 31493434;
PMCID: PMC6801039.

Jones JD, Bisaga A, Metz VE, Manubay JM, Mogali S, Ciccocioppo R, Madera G,
Doernberg M, Comer SD. The PPARγ Agonist Pioglitazone Fails to Alter the Abuse
Potential of Heroin, But Does Reduce Heroin Craving and Anxiety. J Psychoactive
Drugs. 2018 Nov-Dec;50(5):390-401. doi: 10.1080/02791072.2018.1508789. Epub 2018
Sep 11. PMID: 30204554; PMCID: PMC6487639.

Jones JD, Comer SD, Metz VE, Manubay JM, Mogali S, Ciccocioppo R, Martinez S,
Mumtaz M, Bisaga A. Pioglitazone, a PPARγ agonist, reduces nicotine craving in
humans, with marginal effects on abuse potential. Pharmacol Biochem Behav. 2017
Dec;163:90-100. doi: 10.1016/j.pbb.2017.10.002. Epub 2017 Oct 8. PMID: 29020601;
PMCID: PMC5959043.

Jones JD, Manubay JM, Mogali S, Metz VE, Madera G, Martinez S, Mumtaz M,
Comer SD. Abuse liability of intravenous buprenorphine vs.
buprenorphine/naloxone: Importance of absolute naloxone amount. Drug Alcohol
Depend. 2017 Oct 1;179:362-369. doi: 10.1016/j.drugalcdep.2017.06.033. Epub 2017
Jul 26. PMID: 28844013.

Metz VE, Jones JD, Manubay J, Sullivan MA, Mogali S, Segoshi A, Madera G,
Johnson KW, Comer SD. Effects of Ibudilast on the Subjective, Reinforcing, and
Analgesic Effects of Oxycodone in Recently Detoxified Adults with Opioid
Dependence. Neuropsychopharmacology. 2017 Aug;42(9):1825-1832. doi:
10.1038/npp.2017.70. Epub 2017 Apr 10. PMID: 28393896; PMCID: PMC5520790.

Jones JD, Sullivan MA, Manubay JM, Mogali S, Metz VE, Ciccocioppo R, Comer
SD. The effects of pioglitazone, a PPARγ receptor agonist, on the abuse
liability of oxycodone among nondependent opioid users. Physiol Behav. 2016 May
15;159:33-9. doi: 10.1016/j.physbeh.2015.10.006. Epub 2015 Oct 9. PMID:
26455893; PMCID: PMC5444321.

Jones JD, Sullivan MA, Vosburg SK, Manubay JM, Mogali S, Metz V, Comer SD.
Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in
buprenorphine-maintained heroin users. Addict Biol. 2015 Jul;20(4):784-98. doi:
10.1111/adb.12163. Epub 2014 Jul 25. PMID: 25060839; PMCID: PMC4305506.

Mogali S, Khan NA, Drill ES, Pavlicova M, Sullivan MA, Nunes E, Bisaga A.
Baseline characteristics of patients predicting suitability for rapid naltrexone
induction. Am J Addict. 2015 Apr;24(3):258-264. doi: 10.1111/ajad.12180. PMID:
25907815; PMCID: PMC4496800.

Comer SD, Mogali S, Saccone PA, Askalsky P, Martinez D, Walker EA, Jones JD,
Vosburg SK, Cooper ZD, Roux P, Sullivan MA, Manubay JM, Rubin E, Pines A,
Berkower EL, Haney M, Foltin RW. Effects of acute oral naltrexone on the
subjective and physiological effects of oral D-amphetamine and smoked cocaine in
cocaine abusers. Neuropsychopharmacology. 2013 Nov;38(12):2427-38. doi:
10.1038/npp.2013.143. Epub 2013 Jun 5. PMID: 23736314; PMCID: PMC3799062.

Roux P, Sullivan MA, Cohen J, Fugon L, Jones JD, Vosburg SK, Cooper ZD,
Manubay JM, Mogali S, Comer SD. Buprenorphine/naloxone as a promising
therapeutic option for opioid abusing patients with chronic pain: reduction of
pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone. Pain.
2013 Aug;154(8):1442-8. doi: 10.1016/j.pain.2013.05.004. Epub 2013 May 7. PMID:
23707283; PMCID: PMC3770461.

Gudin JA, Mogali S, Jones JD, Comer SD. Risks, management, and monitoring of
combination opioid, benzodiazepines, and/or alcohol use. Postgrad Med. 2013
Jul;125(4):115-30. doi: 10.3810/pgm.2013.07.2684. PMID: 23933900; PMCID:
PMC4057040.

Jones JD, Mogali S, Comer SD. Polydrug abuse: a review of opioid and
benzodiazepine combination use. Drug Alcohol Depend. 2012 Sep 1;125(1-2):8-18.
doi: 10.1016/j.drugalcdep.2012.07.004. Epub 2012 Aug 2. PMID: 22857878; PMCID:
PMC3454351.

Mogali S, Darville K, Pratt LM. Ab initio analysis of lithium
dimethylaminoborohydride. J Org Chem. 2001 Apr 6;66(7):2368-73. doi:
10.1021/jo001600j. PMID: 11281777.

Pratt LM, Mogali S, Glinton K. Solvent effects on the aggregation state of
lithium dialkylaminoborohydrides. J Org Chem. 2003 Aug 22;68(17):6484-8. doi:
10.1021/jo034498+. PMID: 12919007.